Healthcare / Diagnostics & ResearchKOSDAQ
$4355.00
+100.00 (+2.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-10.2B · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$100.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.7%
↓Gross Margin
21.6%
↓Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+224.7%
FCF CAGR
—
FCF margin
-34.5%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $26.05B · net income $-12.34B · FCF $-8.99B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $26.05B | $26.05B | $10.91B | $3.18B | $760.8M |
| Net Income | $-12.34B | $-12.34B | $-17.12B | $-15.77B | $-18.77B |
| EBITDA | $-7.44B | $-7.44B | $-13.75B | $-11.23B | $-13.45B |
| EPS | -535.00 | -535.00 | -758.00 | -862.00 | -1063.00 |
| Gross Margin | 21.6% | 21.6% | 25.9% | 26.6% | 25.7% |
| Operating Margin | -28.7% | -28.7% | -97.8% | -370.3% | -1511.3% |
| Net Margin | -47.4% | -47.4% | -156.9% | -495.2% | -2467.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.31 | 0.33 | 4.67 |
| Current Ratio | 3.44 | 3.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.99B | $-8.99B | $-10.65B | $-10.22B | $-7.12B |
| Returns | |||||
| ROE | -34.7% | -34.7% | -35.2% | -29.6% | -331.9% |
| Valuation | |||||
| P/B | 2.83 | 2.83 | 2.27 | 4.38 | 50.11 |
| Growth & Yield | |||||
| Revenue Growth | 138.8% | 138.8% | 242.6% | 318.6% | — |
| EPS Growth | 29.4% | 29.4% | 12.1% | 18.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-758.00 → -535.00
Residual
+1.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.